Max Crispin
Overview
Explore the profile of Max Crispin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
193
Citations
9438
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee Y, Zhang Y, Newby M, Ward G, Gomes K, Auclair S, et al.
bioRxiv
. 2025 Mar;
PMID: 40060701
One-sentence Summary: Filovirus glycoproteins and nanoparticles were rationally designed and characterized and to aid filovirus vaccine development.
2.
Kumar S, Moral-Sanchez I, Singh S, Newby M, Allen J, Bijl T, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006657
Background: Elite-neutralizer-derived HIV-1 envelopes (Envs), which induce broadly neutralizing antibodies (bnAbs), can inform HIV-1 vaccine design by serving as templates for bnAb-eliciting vaccines. Since single Env-based immunizations are insufficient to...
3.
Wall N, Lamerton R, Ashford F, Perez-Toledo M, Jasiulewicz A, Banham G, et al.
Vaccines (Basel)
. 2025 Jan;
13(1).
PMID: 39852786
: Generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Vaccine-induced immunity is typically reduced in HD populations. The...
4.
Kim Y, Watanabe Y, Arlen-Celina L, Song X, de Oliveira Souza R, Stass R, et al.
NPJ Vaccines
. 2024 Dec;
9(1):243.
PMID: 39690153
Virus-like particles (VLPs) are an established vaccine platform and can be strong immunogens capable of eliciting both humoral and cellular immune responses against a range of pathogens. Here, we show...
5.
Pratap P, Cottrell C, Quinn J, Carnathan D, Bader D, Tran A, et al.
bioRxiv
. 2024 Dec;
PMID: 39651156
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and...
6.
Benjamin S, Jegouzo S, Lieng C, Daniels C, Coispeau M, Lau R, et al.
J Biol Chem
. 2024 Oct;
300(11):107869.
PMID: 39384043
A human lectin array has been developed to probe the interactions of innate immune receptors with pathogenic and commensal microorganisms. Following the successful introduction of a lectin array containing all...
7.
Brinkkemper M, Kerster G, Brouwer P, Tran A, Torres J, Ettema R, et al.
PLoS Pathog
. 2024 Oct;
20(10):e1012558.
PMID: 39361585
An effective human immunodeficiency virus 1 (HIV-1) vaccine will most likely have to elicit broadly neutralizing antibodies (bNAbs) to overcome the sequence diversity of the envelope glycoprotein (Env). So far,...
8.
Kumar S, Moral-Sanchez I, Singh S, Newby M, Allen J, Bijl T, et al.
bioRxiv
. 2024 Sep;
PMID: 39345501
Various design platforms are available to stabilize soluble HIV-1 envelope (Env) trimers, which can be used as antigenic baits and vaccine antigens. However, stabilizing HIV-1 clade C trimers can be...
9.
Caniels T, Medina-Ramirez M, Zhang S, Kratochvil S, Xian Y, Koo J, et al.
Sci Immunol
. 2024 Aug;
9(98):eadk9550.
PMID: 39213338
Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based...
10.
DAddabbo A, Tong T, Crooks E, Osawa K, Xu J, Thomas A, et al.
Glycobiology
. 2024 Aug;
34(11).
PMID: 39115361
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1 infected donors are vaccine paradigms. These bNAbs recognize envelope glycoprotein trimers that carry 75-90 oligomannose and complex-type glycans. Although bNAbs and their precursors...